[AERI] Aerie Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 38.65 Change: 1.45 (3.9%)
Ext. hours: Change: 0 (0%)

chart AERI

Refresh chart

Strongest Trends Summary For AERI

AERI is in the medium-term down -13% in 2 months and down -61% below S&P in 1 year. In the long-term down -72% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, is focused on the discovery, development, and commercialization of first-in-class glaucoma therapies. Its lead product candidate, Rhopressa, is a once-daily triple-action eye drop, which demonstrated the ability to reduce intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension in a Phase 2b clinical trial. The company is conducting two Phase 3 registration trials in the U.S. to demonstrate non-inferiority of IOP lowering for Rhopressa compared to timolol, as well as commencing a third safety-only Phase 3 registration trial of Rhopressa in Canada. It also develops once-daily quadruple-action Roclatan, a single drop combination of Rhopressa with latanoprost, which has completed a 28-day Phase 2b clinical trial. In addition, the company is taking preparatory steps for Phase 3 registration trials for Roclatan. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Bedminster, New Jersey.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-3.31 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-15.12
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-30.07% ROE-120.74% ROI
Current Ratio7.63 Quick Ratio Long Term Debt/Equity Debt Ratio0.46
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities35.07 M Cash From Investing Activities6.1 M Cash From Operating Activities-13.31 M Gross Profit
Net Profit-17.24 M Operating Profit-19.64 M Total Assets195.2 M Total Current Assets170.96 M
Total Current Liabilities22.39 M Total Debt124.19 M Total Liabilities146.58 M Total Revenue
Technical Data
High 52 week60.04 Low 52 week17.72 Last close20.28 Last change2.92%
RSI39.39 Average true range1.47 Beta1.33 Volume623.98 K
Simple moving average 20 days-0.53% Simple moving average 50 days-6.05% Simple moving average 200 days-40.58%
Performance Data
Performance Week8.28% Performance Month-14.93% Performance Quart-15.57% Performance Half-51.94%
Performance Year-63.37% Performance Year-to-date-43.82% Volatility daily4.76% Volatility weekly10.64%
Volatility monthly21.81% Volatility yearly75.54% Relative Volume235.1% Average Volume1.26 M
New High New Low


2019-11-12 07:30:00 | Aerie Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference

2019-11-07 10:51:03 | Aerie AERI Q3 Loss Wider, Sales Beat, Guidance Slashed

2019-11-07 07:18:13 | The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

2019-11-07 02:53:36 | Edited Transcript of AERI earnings conference call or presentation 6-Nov-19 10:00pm GMT

2019-11-06 18:05:11 | Aerie Pharmaceuticals AERI Reports Q3 Loss, Tops Revenue Estimates

2019-11-06 16:01:00 | Aerie Pharmaceuticals Reports Third Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update

2019-11-05 06:30:00 | Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil Ophthalmic Solution in Phase 2 Study Conducted in Japan

2019-10-30 07:30:00 | Aerie Pharmaceuticals to Announce Third Quarter 2019 Financial Results and Host Conference Call on Wednesday, November 6, 2019

2019-10-30 06:30:00 | Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, M.D., M.B.A., as Chief Research & Development Officer

2019-10-29 10:33:02 | Aerie Pharmaceuticals AERI Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

2019-10-28 18:13:44 | Is Aerie Pharmaceuticals Inc AERI Going To Burn These Hedge Funds ?

2019-10-25 06:40:23 | Imagine Owning Aerie Pharmaceuticals NASDAQ:AERI While The Price Tanked 62%

2019-10-24 06:30:00 | Aerie Pharmaceuticals Completes Enrollment in the Phase 2 Trial of AR-1105 Dexamethasone Intravitreal Implant in Patients with Macular Edema Associated with Retinal Vein Occlusion Ahead of Schedule

2019-10-07 06:30:00 | Aerie Pharmaceuticals Announces Appointment of Charlene E. Davis, Esq., as Vice President and Chief Compliance Officer

2019-09-25 07:30:00 | Aerie Pharmaceuticals to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

2019-09-23 13:20:05 | Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa

2019-09-20 06:30:00 | Aerie Pharmaceuticals Receives Positive CHMP Opinion for Rhokiinsa® in the European Union

2019-09-19 07:39:31 | The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO

2019-09-19 06:37:54 | Will Aerie Pharmaceuticals, Inc. NASDAQ:AERI Need To Raise More Money?

2019-09-19 06:30:00 | Aerie Pharmaceuticals Submits Prior Approval Supplement to the U.S. Food and Drug Administration to Allow Production of Rocklatan® netarsudil and latanoprost ophthalmic solution 0.02%/0.005% in its Athlone Ireland Facility

2019-09-16 11:46:52 | Weekly CEO Buys Highlight

2019-09-10 21:36:00 | Aerie Pharmaceuticals Announces Full Exercise by Initial Purchasers of Option to Purchase Additional $41.25 Million Aggregate Principal Amount of Aerie’s 1.50% Convertible Senior Notes Due 2024

2019-09-09 19:15:04 | Aerie Pharmaceuticals Inc AERI CEO Vicente Jr Anido Bought $499,012 of Shares

2019-09-09 06:00:00 | These 2 Biotech Stocks Are Seeing Insider Buying Activity

2019-09-06 14:42:00 | Durham pharma embarks on $275M financial trade

2019-09-06 09:31:01 | Aerie AERI Down 19.7% Since Last Earnings Report: Can It Rebound?

2019-09-05 08:12:42 | The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug

2019-09-04 20:20:00 | Aerie Pharmaceuticals Upsizes and Prices Private Offering of $275 Million 1.50% Convertible Senior Notes Due 2024

2019-09-03 16:01:00 | Aerie Pharmaceuticals to Offer $250 Million Convertible Senior Notes Due 2024

2019-08-26 06:30:00 | Aerie Pharmaceuticals Announces Appointment of Luis Vargas, M.D., as Medical Director, Medical Affairs

2019-08-20 06:30:00 | Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema

2019-08-19 13:56:47 | Zuckerberg Sells Shares of Facebook

2019-08-08 16:08:47 | This Biotech Crashed On 'Erroneous' Report — Plus 2 Stocks That Diverged

2019-08-08 09:25:01 | Aerie AERI Beats on Q2 Earnings & Sales, Lowers Guidance

2019-08-08 09:02:35 | Aerie Pharmaceuticals, Inc.'s NASDAQ:AERI Path To Profitability

2019-08-08 04:05:55 | Edited Transcript of AERI earnings conference call or presentation 7-Aug-19 9:00pm GMT

2019-08-08 01:50:14 | Aerie Pharmaceuticals, Inc. AERI Q2 2019 Earnings Call Transcript

2019-08-07 18:05:10 | Aerie Pharmaceuticals AERI Reports Q2 Loss, Tops Revenue Estimates

2019-08-07 16:01:00 | Aerie Pharmaceuticals Reports Second Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update

2019-07-31 10:36:02 | Will Aerie Pharmaceuticals AERI Report Negative Earnings Next Week? What You Should Know

2019-07-28 21:23:28 | Analysts Recommend Buying These 2 Falling Knives

2019-07-25 07:30:00 | Aerie Pharmaceuticals to Announce Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 7, 2019

2019-07-18 18:26:10 | Allergan Announces FDA Acceptance of Glaucoma Candidate NDA

2019-07-18 08:22:21 | Hatteras Ventures-backed firm adds fresh round of capital

2019-07-11 06:46:00 | How a Durham firm stands to benefit from an unexpected break in a Japanese trial

2019-07-09 17:48:09 | Aerie Completes Enrollment Under Rhopressa Study in Japan

2019-07-09 06:30:00 | Aerie Pharmaceuticals Completes Enrollment of the Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Months Ahead of Schedule

2019-06-24 08:50:12 | Ocular OCUL Gets FDA Nod for Label Expansion of Dextenza

2019-06-20 19:09:44 | Is Aerie Pharmaceuticals Inc AERI A Good Stock To Buy?

2019-06-18 08:05:56 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.